http://www.loc.gov/mods/v3 http://www.loc.gov/standards/mods/v3/mods-3-2.xsd
CRISPR-CAS system in translational biotechnology
Front Cover -- CRISPR-Cas System in Translational Biotechnology -- Copyright Page -- Contents -- List of contributors -- 1 CRISPR-Cas fundamentals and advances -- 1 CRISPR-Cas9: chronology and evolution -- 1.1 Introduction -- 1.2 Discovery of CRISPR-Cas system -- 1.3 Mechanism of CRISPR-Cas system -- 1.4 Classification of CRISPR-Cas system -- 1.4.1 Class I CRISPR-Cas system -- 1.4.1.1 Type I -- 1.4.1.2 Type III -- 1.4.1.3 Type IV -- 1.4.2 Class II CRISPR-Cas system -- 1.4.2.1 Type II system -- 1.4.2.2 Type V system -- 1.4.2.3 Type VI system -- 1.5 Limitations of CRISPR technology
1.5.1 CRISPR-Cas9 off-target effects -- 1.5.2 DNA damage and apoptosis -- 1.5.3 Immunotoxicity -- 1.5.4 Delivery of CRISPR system to hosts -- 1.6 Applications of CRISPR technology -- 1.6.1 Role of CRISPR in gene regulation -- 1.6.2 In metabolic engineering -- 1.6.3 Role of CRISPR in COVID-19 -- 1.6.4 CRISPR for animal model preparation -- 1.7 Conclusions and future perspectives -- References -- 2 CRISPR: the Janus god of modern science -- 2.1 Introduction -- 2.2 Timeline of developments in CRISPR-Cas system -- 2.3 Applications of CRISPR-Cas gene-editing system in human diseases
2.3.1 In the treatment of genetic disorders -- 2.3.2 In the treatment of various types of cancer -- 2.3.3 In the treatment of acquired immunodeficiency syndrome -- 2.3.4 In the treatment of neurodegenerative disorders -- 2.3.5 In Coronavirus disease 2019 -- 2.4 Applications of CRISPR system in agriculture for crop improvement -- 2.4.1 Increasing productivity -- 2.4.2 Quality improvement -- 2.4.3 Tolerance to biotic and abiotic stress -- 2.4.4 Herbicide resistance -- 2.4.5 Expediting hybrid breeding -- 2.5 Applications of CRISPR-Cas9 system in environmental science -- 2.5.1 Bioplastic
2.5.2 Biofuel -- 2.5.3 Biosensors -- 2.5.4 Bioremediation -- 2.6 Limitations of CRISPR-Cas9 gene-editing system in medicinal, agricultural, and environmental sectors -- 2.6.1 Limitations of CRISPR in the medicinal field -- 2.6.1.1 Mutations -- 2.6.1.2 Immunotoxicity -- 2.6.2 Limitations of CRISPR in agricultural crops -- 2.6.3 Limitations of CRISPR on the environment -- 2.6.4 Implications for Cas and mitigating strategies -- 2.7 Conclusions -- References -- 3 Commercialization of CRISPR-Cas technology: issues and impact -- 3.1 Introduction -- 3.2 CRISPR-Cas IPR dispute: who stands where?
3.3 Worldwide patent landscape of CRISPR -- 3.4 A commercial conundrum -- 3.5 Ethical concerns -- 3.6 Challenges in commercialization of CRISPR-Cas -- 3.6.1 Agriculture -- 3.6.2 Medicine -- 3.7 Conclusions -- References -- 2 CRISPR-Cas in medical biotechnology -- 4 CRISPR-Cas-led advancements in translational biotechnology -- 4.1 Introduction -- 4.2 Genome editing tools before CRISPR -- 4.2.1 Zinc finger nucleases -- 4.2.2 Transcription activator-like effector nucleases -- 4.2.3 Adeno-associated viruses -- 4.3 CRISPR technology -- 4.3.1 Components of CRISPR -- 4.3.2 Cas enzymes -- 4.3.2.1 Cas9
edited by Swati Joshi, Digvijay Verma, Ravi Kr. Gupta.